119 related articles for article (PubMed ID: 22996619)
21. Nursing care of clients treated with atypical antipsychotics who have a risk of developing metabolic instability and/or type 2 diabetes.
Edward KL; Rasmussen B; Munro I
Arch Psychiatr Nurs; 2010 Feb; 24(1):46-53. PubMed ID: 20117688
[TBL] [Abstract][Full Text] [Related]
22. Metabolic considerations in the use of antipsychotic medications: a review of recent evidence.
Newcomer JW
J Clin Psychiatry; 2007; 68 Suppl 1():20-7. PubMed ID: 17286524
[TBL] [Abstract][Full Text] [Related]
23. Metabolic syndrome and associated cardiovascular risk factors in the treatment of persons with human immunodeficiency virus and severe mental illness.
Vergara-Rodriguez P; Vibhakar S; Watts J
Pharmacol Ther; 2009 Dec; 124(3):269-78. PubMed ID: 19647020
[TBL] [Abstract][Full Text] [Related]
24. [Prescribing patterns of antipsychotics in 13 French psychiatric hospitals].
Bret P; Bret MC; Queuille E
Encephale; 2009 Apr; 35(2):129-38. PubMed ID: 19393381
[TBL] [Abstract][Full Text] [Related]
25. Metabolic syndrome: epidemiology and consequences.
Sacks FM
J Clin Psychiatry; 2004; 65 Suppl 18():3-12. PubMed ID: 15600380
[TBL] [Abstract][Full Text] [Related]
26. Cutaneous adverse reactions to psychotropic drugs: data from a multicenter surveillance program.
Lange-Asschenfeldt C; Grohmann R; Lange-Asschenfeldt B; Engel RR; Rüther E; Cordes J
J Clin Psychiatry; 2009 Sep; 70(9):1258-65. PubMed ID: 19538904
[TBL] [Abstract][Full Text] [Related]
27. Clinical monitoring and management of the metabolic syndrome in patients receiving atypical antipsychotic medications.
Hasnain M; Vieweg WV; Fredrickson SK; Beatty-Brooks M; Fernandez A; Pandurangi AK
Prim Care Diabetes; 2009 Feb; 3(1):5-15. PubMed ID: 19083283
[TBL] [Abstract][Full Text] [Related]
28. Modal subcomponents of metabolic syndrome in patients with bipolar disorder.
Cardenas J; Frye MA; Marusak SL; Levander EM; Chirichigno JW; Lewis S; Nakelsky S; Hwang S; Mintz J; Altshuler LL
J Affect Disord; 2008 Feb; 106(1-2):91-7. PubMed ID: 17628693
[TBL] [Abstract][Full Text] [Related]
29. Obesity and metabolic syndrome in a psychiatric rehabilitation service.
Tirupati S; Chua LE
Aust N Z J Psychiatry; 2007 Jul; 41(7):606-10. PubMed ID: 17558623
[TBL] [Abstract][Full Text] [Related]
30. The METEOR study: frequency of metabolic disorders in patients with schizophrenia. Focus on first and second generation and level of risk of antipsychotic drugs.
Falissard B; Mauri M; Shaw K; Wetterling T; Doble A; Giudicelli A; De Hert M
Int Clin Psychopharmacol; 2011 Nov; 26(6):291-302. PubMed ID: 21876442
[TBL] [Abstract][Full Text] [Related]
31. Beyond the "hype" on the association between metabolic syndrome and atypical antipsychotics: the confounding effects of cohort, typical antipsychotics, severe mental illness, comedications, and comorbid substance use.
de Leon J
J Clin Psychopharmacol; 2008 Apr; 28(2):125-31. PubMed ID: 18344721
[No Abstract] [Full Text] [Related]
32. Comparison of insulin resistance, metabolic syndrome and adiponectin in overweight bipolar patients taking sodium valproate and controls.
Elmslie JL; Porter RJ; Joyce PR; Hunt PJ; Shand BI; Scott RS
Aust N Z J Psychiatry; 2009 Jan; 43(1):53-60. PubMed ID: 19085528
[TBL] [Abstract][Full Text] [Related]
33. National trends in psychotropic medication polypharmacy in office-based psychiatry.
Mojtabai R; Olfson M
Arch Gen Psychiatry; 2010 Jan; 67(1):26-36. PubMed ID: 20048220
[TBL] [Abstract][Full Text] [Related]
34. [Risk factors for inactivity in patients in long-term care with severe mental illness].
Tenback DE; van Kessel F; Jessurun J; Pijl YJ; Heerdink ER; van Harten PN
Tijdschr Psychiatr; 2013; 55(2):83-91. PubMed ID: 23408360
[TBL] [Abstract][Full Text] [Related]
35. Psychotropic drugs and the risk of fall injuries, hospitalisations and mortality among older adults.
Johnell K; Jonasdottir Bergman G; Fastbom J; Danielsson B; Borg N; Salmi P
Int J Geriatr Psychiatry; 2017 Apr; 32(4):414-420. PubMed ID: 27113813
[TBL] [Abstract][Full Text] [Related]
36. Multiple versus single antipsychotic agents for hospitalized psychiatric patients: case-control study of risks versus benefits.
Centorrino F; Goren JL; Hennen J; Salvatore P; Kelleher JP; Baldessarini RJ
Am J Psychiatry; 2004 Apr; 161(4):700-6. PubMed ID: 15056517
[TBL] [Abstract][Full Text] [Related]
37. Antipsychotic prescription and mortality in hospitalized older persons.
Chiesa D; Marengoni A; Nobili A; Tettamanti M; Pasina L; Franchi C; Djade CD; Corrao S; Salerno F; Marcucci M; Romanelli G; Mannucci PM;
Psychogeriatrics; 2017 Nov; 17(6):397-405. PubMed ID: 28589693
[TBL] [Abstract][Full Text] [Related]
38. Interest of pharmacoepidemiology for the study of psychotropic drugs.
Tournier M; Montastruc F
Therapie; 2019 Apr; 74(2):239-244. PubMed ID: 30792080
[TBL] [Abstract][Full Text] [Related]
39. Metabolic syndrome and psychotropic medications.
Filaković P; Petek Erić A; Radanović-Grgurić L
Med Glas (Zenica); 2012 Aug; 9(2):180-8. PubMed ID: 22926348
[TBL] [Abstract][Full Text] [Related]
40. [Antipsychotics and metabolic abnormalities in children and adolescents: a review of the literature and some recommendations].
Overbeek WA; de Vroede MA; Lahuis BE; Hillegers MH; de Graeff-Meeder ER
Tijdschr Psychiatr; 2010; 52(5):311-20. PubMed ID: 20458678
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
